Follow us:

PCC®

Lactobacillus fermentum PCC® was discovered in 1988 after testing more than 400 different strains. More than 30 million Australian dollars (15M EUR) was invested in the research of the strain.

Strain deposit number: NM02/31074

PCC® has been consumed and well tolerated since 2002 in commercially available products. Chr. Hansen bought global exclusive rights to PCC® in November 2009.

An award-winning strain

On 16 November 2010 at Health Ingredients Europe Chr. Hansen was awarded the prestigious Health Ingredients Excellence Award within the Sport Performance category for PCC®.

Health Area

Human studies indicate that PCC® has a beneficial effect within immune health.

The Benefits of PCC®

Studies indicate that PCC®:

  • Induces a protective immune response
  • Induces an enhanced immune response to an influenza vaccine

Clinical Documentation

The many beneficial effects of the PCC® strain makes it an excellent choice for a series of health areas, which you will also see from Chr. Hansen's probiotic product offerings handout (PDF, 461 KB).

Please contact our Sales Directors to learn more about your possibilities of using PCC® in your probiotic product.

Contact

Contact the dedicated Chr. Hansen Sales departments - they will help you find the perfect product with strains from Chr. Hansen's Probio-Tec® range.

Downloads

PCC® Selected Summaries
PCC® Selected SummariesThis binder provides you with summaries of selected publications on PCC®
PCC® - Handout
PCC® - HandoutChr. Hansen offers multiple application forms of our clinically documented Probio-Tec® strain,...